Security key
09058V103
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)
CUSIP: 09058V103
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, $0.01 par value per share
- Total 13F shares
- 249,271,140
- Total 13F value
- $2,372,721,135
- Share change
- +35,815,274
- Put/Call ratio
- 45%
- SEC-reported price per share
- $9.52
- Number of holders
- 302
- Value change
- +$366,307,768
- Number of buys
- 182
- Number of sells
- 117
- Shares outstanding
- 255,277,194
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
302
Top holders
10
BCRX full security history
Ownership snapshot
Full 13F holder table
BIOCRYST PHARMACEUTICALS INC SEC filings
BIOCRYST PHARMACEUTICALS INC company facts
Broader feeds
Ownership snapshot
Top reported holders of BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 8.4%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.4%
James E. Flynn
6.8%
VANGUARD CAPITAL MANAGEMENT LLC
5.2%
Avoro Capital Advisors LLC
4.2%
Charles K. Gayer
0.37%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.4%
from 13D/G
|
$164,874,767
21,137,791 shares
|
— | 31 Dec 2025 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
6.8%
|
$109,278,420
14,341,000 shares
|
+$16,550,640 | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
Vanguard Capital Management
|
5.2%
|
$123,390,357
12,961,172 shares
|
$0 | 31 Mar 2026 |
| Avoro Capital Advisors LLC |
13D/G
|
4.2%
|
$71,514,000
8,700,000 shares
|
$0 | 31 Mar 2025 |
| Charles K. Gayer |
3/4/5
President and CCO
|
0.37%
|
$5,248,732
952,583 shares
|
— | 19 Dec 2025 |
| Ronald Dullinger |
3/4/5
Chief Commercial Officer
|
0.1%
|
$2,015,146
258,372 shares
|
— | 01 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
302
Shares
249,271,140
Rows available
302
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
302
Q1 2026 holders
302
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|